Changes in Beneficial Ownership · 4
Liquidia Corporation
LQDANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2625466-1_4seq1.xml
Filing details
- Report period
- 2026-09-11
- Issuer
- Liquidia Corp
- Issuer CIK
- 0001819576
- Trading symbol
- LQDA
Reporting owner 1
- Name
- SINGH RAMAN
- Reporting owner CIK
- 0001747589
- Relationship
- Director
- Address
- 419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-11 | M · Form 4 | 556 | A | 8.63 | 45,193[F1] | D |
| Common Stock | 2026-09-11 | M · Form 4 | 8,468 | A | 9.3055 | 53,661[F1] | D |
| Common Stock | 2026-09-11 | S · Form 4[F2] | 9,024 | D | 68.6181[F3] | 44,637[F1] | D |
| Common Stock | 2026-09-14 | M · Form 4 | 8,468 | A | 9.3055 | 53,105[F1] | D |
| Common Stock | 2026-09-14 | S · Form 4[F2] | 8,468 | D | 66.16 | 44,637[F1] | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | 8.63 | 2026-09-11 | M · Form 4 | 556 | D | 0 | 2026-06-19[F4] | 2033-06-19 | Common Stock | 556 | 0 | D |
| Non-Qualified Stock Option (right to buy) | 9.3055 | 2026-09-11 | M · Form 4 | 8,468 | D | 0 | 2021-03-07[F5] | 2028-03-07 | Common Stock | 8,468 | 8,468 | D |
| Non-Qualified Stock Option (right to buy) | 9.3055 | 2026-09-14 | M · Form 4 | 8,468 | D | 0 | 2021-03-07[F5] | 2028-03-07 | Common Stock | 8,468 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Includes 5,882 restricted stock units granted to the Reporting Person on June 16, 2026, none of which have vested as of the date of this Form 4.↩ 1↩ 2↩ 3↩ 4↩ 5
- F2
- Represents the subsequent sale of the underlying shares from the exercise of stock options reported on this Form 4.↩ 1↩ 2
- F3
- Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $68.60 to $68.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F4
- The option vested in 36 equal monthly installments and became fully vested on June 19, 2026.↩ 1
Signature 1
- Signed
- /s/ Raman Singh
- Date
- 2026-09-15
Company context
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, approved for the treatment of pulmonary arterial hypertension (PAH), and in development for Raynaud’s phenomenon secondary to systemic sclerosis (SSc-RP). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily via a next-generation nebulizer to treat PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). To learn more about Liquidia, please visit www.liquidia.com.